Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × MAGEA3 protein, human × Dermatologic × Clear all
NCT00074230 2015-05-12

Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma

University Hospital Erlangen

Phase 1/2 Completed
82 enrolled
Dermatologic

Melanoma

NCT00002952 2013-09-05

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

University of Chicago

Phase 1/2 Completed
20 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡